In a clinical study, targeted sequencing of tumour and patient-matched normal DNA samples, from FFPE or peripheral blood, on 348 patients treated with palbociclib, ribociclib, or abemaciclib correlated FAT1 alterations with reduced PFS. This evidence concerns the gene FAT1 and neoplasm.